Leadership & Pay ·
On August 25, 2026, REGENXBIO Inc.'s Board elected Gregory Ciongoli as a Class II director and appointed him to the…
RGNXREGENXBIO Inc.
On August 25, 2026, REGENXBIO Inc.'s Board elected Gregory Ciongoli as a Class II director and appointed him to the Audit and Nominating committees. Concurrently, directors Jean Bennett and A.N. "Jerry" Karabelas resigned from the Board but will serve as advisors until February 2027. The Board reduced its size to nine members. Mr. Ciongoli received an initial equity award valued at $550,000 comprising stock options with a $8.91 exercise price and restricted stock units, along with annual retainers totaling $60,000. REGENXBIO is a biotechnology company focused on developing AAV gene therapies for rare and retinal diseases.